Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flotetuzumab
- Development stage
- Phase 2
- Lead developer
- MacroGenics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Flotetuzumab is a clinical-stage, investigational bispecific DART (Dual-Affinity ReTargeting) molecule designed to recognize both CD123, the interleukin-3 receptor alpha chain overexpressed on malignant cells in acute myeloid leukemia (AML) and other hematologic malignancies, and CD3, an activating molecule expressed by T cells. By binding to both targets simultaneously, flotetuzumab redirects T lymphocytes to kill CD123-expressing tumor cells through antibody-dependent cell cytotoxicity and T cell activation. The drug has been primarily developed for relapsed or refractory AML and has received orphan drug designation for this indication[1][4][5][6][7].
- Other names
- Anti-CD123/CD3-monoclonal-antibody-MGD006
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on flotetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flotetuzumab.